melanotic schwannian tumor Malignant nerve sheath with PRKAR1A, KMT2C and GNAQ mutations Malignant melanotic nerve sheath tumor
Description
doi: 10.1001/jama.2016.17441 25 NegroMMarzulloNCasoFCalanni PirelliLDAntonaG
The FDA-approved label for Vyleesi reports that about 40 percent of patients experience nausea, and a meaningful percentage of patients either need anti-nausea medication or stop treatment because of it
Tissue interactions in neural crest cell development and disease
Seshacharyulu P et al
Front Immunol (2018) 9:367
